Suppr超能文献

表皮生长因子受体突变的 II-III 期肺腺癌中优势亚型的预后价值。

Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.

机构信息

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

出版信息

Lung Cancer. 2024 Feb;188:107453. doi: 10.1016/j.lungcan.2023.107453. Epub 2023 Dec 30.

Abstract

OBJECTIVES

This study extracted clinicopathological features associated with recurrence and evaluated the tumor microenvironment in consecutive cases with resected pathological stage II-III epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (EGFR-mt).

METHODS

Between January 2008 and November 2018, we retrospectively reviewed 387 consecutive patients with pathological stage II-III lung adenocarcinoma who underwent surgical resection. We examined the EGFR mutation status (wild-type or mutant) and the evaluated clinicopathological features of all patients. In addition, tumor-promoting cancer-associated fibroblasts (CAFs), tumor-associated M2 macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment of EGFR-mt cells were evaluated by immunohistochemical analysis.

RESULTS

EGFR-mt (n = 124, 32 %) had more lymph node and pulmonary metastases than EGFR-wild-type lung adenocarcinoma (EGFR-wt) despite the smaller invasive component size. The disease-free survival (DFS) of patients with EGFR-mt tended to be shorter than that of patients with EGFR-wt. In the analysis according to the predominant subtype, EGFR-mt with papillary-predominant subtype had a significantly shorter 5-year DFS than that of EGFR-wt with papillary-predominant subtype (15.3 % vs. 44.1 %, p < 0.01). We observed no significant differences among the other subtypes. Multivariate analysis of DFS in patients with EGFR-mt revealed that male sex, pathological stage III, lymph node metastasis, pulmonary metastasis in the same lobe and non-acinar and non-lepidic predominant subtypes (papillary, solid, or micropapillary) were independent poor prognostic factors. Immunohistochemical analysis of EGFR-mt revealed that non-acinar- and non-lepidic-predominant subtypes were associated with a higher frequency of podoplanin-positive CAFs (36 % vs. 13 %, p = 0.01) and a higher median number of CD204-positive TAMs (61 vs. 49, p = 0.07) compared to the acinar- or lepidic-predominant subtypes.

CONCLUSIONS

Non-acinar and non-lepidic predominant subtypes were predictors of recurrence and had an aggressive tumor microenvironment in pathological stage II-III EGFR-mt.

摘要

目的

本研究提取了与复发相关的临床病理特征,并评估了连续切除的病理 II-III 期表皮生长因子受体(EGFR)突变型肺腺癌(EGFR-mt)的肿瘤微环境。

方法

2008 年 1 月至 2018 年 11 月,我们回顾性分析了 387 例连续接受手术切除的病理 II-III 期肺腺癌患者。我们检查了 EGFR 突变状态(野生型或突变型)和所有患者的评估临床病理特征。此外,通过免疫组织化学分析评估 EGFR-mt 肿瘤微环境中的促肿瘤癌相关成纤维细胞(CAFs)、肿瘤相关 M2 巨噬细胞(TAMs)和肿瘤浸润淋巴细胞(TILs)。

结果

尽管侵袭性成分较小,但 EGFR-mt(n=124,32%)的淋巴结和肺转移更多。EGFR-mt 患者的无病生存期(DFS)似乎短于 EGFR-wt 患者。根据主要亚型进行分析时,以乳头为主型的 EGFR-mt 患者的 5 年 DFS 明显短于以乳头为主型的 EGFR-wt 患者(15.3% vs. 44.1%,p<0.01)。我们在其他亚型中未观察到显著差异。EGFR-mt 患者 DFS 的多变量分析显示,男性、病理分期 III 期、淋巴结转移、同侧肺和非腺泡及非鳞屑型为主(乳头、实体或微乳头)是独立的不良预后因素。EGFR-mt 的免疫组织化学分析显示,非腺泡和非鳞屑型为主的亚型与较高的 podoplanin 阳性 CAFs 频率相关(36% vs. 13%,p=0.01)和较高的中位 CD204 阳性 TAMs 数量(61 与 49,p=0.07)相比,以腺泡或鳞屑为主的亚型。

结论

非腺泡和非鳞屑型为主的亚型是复发的预测因素,在病理 II-III 期 EGFR-mt 中具有侵袭性肿瘤微环境。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验